Dasatinib Accord

Country: European Union

Language: Icelandic

Source: EMA (European Medicines Agency)

Active ingredient:

dasatinib

Available from:

Accord Healthcare S.L.U.

ATC code:

L01EA02

INN (International Name):

dasatinib (anhydrous)

Therapeutic group:

Æxlishemjandi lyf

Therapeutic area:

Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Therapeutic indications:

Dasatinib Accord is indicated for the treatment of adult patients with:• Ph+ acute lymphoblastic leukaemia (ALL) with resistance or intolerance to prior therapy. Dasatinib Accord is indicated for the treatment of paediatric patients with:• newly diagnosed Ph+ ALL in combination with chemotherapy.

Product summary:

Revision: 1

Authorization status:

Aftakað

Authorization date:

2022-03-24

Patient Information leaflet

                                49
B. FYLGISEÐILL
Lyfið er ekki lengur með markaðsleyfi
50
FYLGISEÐILL: UPPLÝSINGAR FYRIR NOTANDA LYFSINS
DASATINIB ACCORD 20 MG FILMUHÚÐAÐAR TÖFLUR
DASATINIB ACCORD 50 MG FILMUHÚÐAÐAR TÖFLUR
DASATINIB ACCORD 70 MG FILMUHÚÐAÐAR TÖFLUR
DASATINIB ACCORD 80 MG FILMUHÚÐAÐAR TÖFLUR
DASATINIB ACCORD 100 MG FILMUHÚÐAÐAR TÖFLUR
DASATINIB ACCORD 140 MG FILMUHÚÐAÐAR TÖFLUR
dasatinib
LESIÐ ALLAN FYLGISEÐILINN VANDLEGA ÁÐUR EN BYRJAÐ ER AÐ TAKA
LYFIÐ. Í HONUM ERU MIKILVÆGAR
UPPLÝSINGAR.

Geymið fylgiseðilinn. Nauðsynlegt getur verið að lesa hann
síðar.

Leitið til læknisins eða lyfjafræðings ef þörf er á frekari
upplýsingum.

Þessu lyfi hefur verið ávísað til persónulegra nota. Ekki má
gefa það öðrum. Það getur valdið
þeim skaða, jafnvel þótt um sömu sjúkdómseinkenni sé að
ræða.

Látið lækninn eða lyfjafræðing vita um allar aukaverkanir.
Þetta gildir einnig um aukaverkanir
sem ekki er minnst á í þessum fylgiseðli. Sjá kafla 4.
Í FYLGISEÐLINUM ERU EFTIRFARANDI KAFLAR:
1.
Upplýsingar um Dasatinib Accord og við hverju það er notað
2.
Áður en byrjað er að nota Dasatinib Accord
3.
Hvernig nota á Dasatinib Accord
4.
Hugsanlegar aukaverkanir
5.
Hvernig geyma á Dasatinib Accord
6.
Pakkningar og aðrar upplýsingar
1.
UPPLÝSINGAR UM DASATINIB ACCORD OG VIÐ HVERJU ÞAÐ ER NOTAÐ
Dasatinib Accord inniheldur virka efnið dasatinib. Þetta lyf er
notað til að meðhöndla
Fíladelfíulitnings jákvætt (Ph+) brátt hvítblæði í
eitilfrumum (ALL). Það er notað hjá fullorðnum sem
ekki hafa haft gagn af fyrri meðferðum sem og í samsetningu með
öðrum krabbameinslyfjum hjá
unglingum og börnum sem hafa náð a.m.k. 1 árs aldri með nýlega
greint Ph+ ALL. Hjá sjúklingum
með ALL fjölga hvítfrumur sem kallaðar eru eitilfrumur sér of
hratt og þær lifa of lengi. Dasatinib
Accord hindrar fjölgun þessara hvítblæðisfrumna.
Hafir þú einhverjar spurningar varðandi verkunarmáta Dasatinib
Accord eða
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
VIÐAUKI I
SAMANTEKT Á EIGINLEIKUM LYFS
Lyfið er ekki lengur með markaðsleyfi
2
1.
HEITI LYFS
Dasatinib Accord 20 mg filmuhúðaðar töflur
Dasatinib Accord 50 mg filmuhúðaðar töflur
Dasatinib Accord 70 mg filmuhúðaðar töflur
Dasatinib Accord 80 mg filmuhúðaðar töflur
Dasatinib Accord 100 mg filmuhúðaðar töflur
Dasatinib Accord 140 mg filmuhúðaðar töflur
2.
INNIHALDSLÝSING
Dasatinib Accord 20 mg filmuhúðaðar töflur
Hver filmuhúðuð tafla inniheldur 20 mg dasatinib.
_Hjálparefni með þekkta verkun _
Hver filmuhúðuð tafla inniheldur 27 mg af laktósa (sem
einhýdrat).
Dasatinib Accord 50 mg
filmuhúðaðar töflur
Hver filmuhúðuð tafla inniheldur 50 mg dasatinib.
_Hjálparefni með þekkta verkun _
Hver filmuhúðuð tafla inniheldur 67,5 mg af laktósa (sem
einhýdrat).
Dasatinib Accord 70 mg
filmuhúðaðar töflur
Hver filmuhúðuð tafla inniheldur 70 mg dasatinib.
_Hjálparefni með þekkta verkun _
Hver filmuhúðuð tafla inniheldur 94,5 mg af laktósa (sem
einhýdrat).
Dasatinib Accord 80 mg
filmuhúðaðar töflur
Hver filmuhúðuð tafla inniheldur 80 mg dasatinib.
_Hjálparefni með þekkta verkun _
Hver filmuhúðuð tafla inniheldur 108 mg af laktósa (sem
einhýdrat).
Dasatinib Accord
100 mg filmuhúðaðar töflur
Hver filmuhúðuð tafla inniheldur 100 mg dasatinib.
_Hjálparefni_
_ með þekkta verkun _
Hver filmuhúðuð tafla inniheldur 135,0 mg af laktósa (sem
einhýdrat).
Dasatinib Accord
140 mg filmuhúðaðar töflur
Hver filmuhúðuð tafla inniheldur 140 mg dasatinib.
_Hjálparefni með þekkta verkun _
Hver filmuhúðuð tafla inniheldur 189 mg af laktósa (sem
einhýdrati).
Sjá lista yfir öll hjálparefni í kafla 6.1.
3.
LYFJAFORM
Filmuhúðuð tafla (tafla).
Dasatinib Accord 20 mg
filmuhúðaðar töflur
Hvítar til beinhvítar, kringlóttar húðaðar töflur, 5,6 mm í
þvermál, með „DAS“ greypt í aðra hliðina og
Lyfið er ekki lengur með markaðsleyfi
3
„20“ í hina.
Dasatinib Accord 50 mg
filmuhúðaðar töflur
Hvítar til 
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 30-03-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 30-03-2023
Public Assessment Report Public Assessment Report Bulgarian 30-03-2023
Patient Information leaflet Patient Information leaflet Spanish 30-03-2023
Public Assessment Report Public Assessment Report Spanish 30-03-2023
Patient Information leaflet Patient Information leaflet Czech 30-03-2023
Public Assessment Report Public Assessment Report Czech 30-03-2023
Patient Information leaflet Patient Information leaflet Danish 30-03-2023
Public Assessment Report Public Assessment Report Danish 30-03-2023
Patient Information leaflet Patient Information leaflet German 30-03-2023
Public Assessment Report Public Assessment Report German 30-03-2023
Patient Information leaflet Patient Information leaflet Estonian 30-03-2023
Public Assessment Report Public Assessment Report Estonian 30-03-2023
Patient Information leaflet Patient Information leaflet Greek 30-03-2023
Public Assessment Report Public Assessment Report Greek 30-03-2023
Patient Information leaflet Patient Information leaflet English 30-03-2023
Public Assessment Report Public Assessment Report English 30-03-2023
Patient Information leaflet Patient Information leaflet French 30-03-2023
Public Assessment Report Public Assessment Report French 30-03-2023
Patient Information leaflet Patient Information leaflet Italian 30-03-2023
Public Assessment Report Public Assessment Report Italian 30-03-2023
Patient Information leaflet Patient Information leaflet Latvian 30-03-2023
Public Assessment Report Public Assessment Report Latvian 30-03-2023
Patient Information leaflet Patient Information leaflet Lithuanian 30-03-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 30-03-2023
Public Assessment Report Public Assessment Report Lithuanian 30-03-2023
Patient Information leaflet Patient Information leaflet Hungarian 30-03-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 30-03-2023
Public Assessment Report Public Assessment Report Hungarian 30-03-2023
Patient Information leaflet Patient Information leaflet Maltese 30-03-2023
Public Assessment Report Public Assessment Report Maltese 30-03-2023
Patient Information leaflet Patient Information leaflet Dutch 30-03-2023
Public Assessment Report Public Assessment Report Dutch 30-03-2023
Patient Information leaflet Patient Information leaflet Polish 30-03-2023
Public Assessment Report Public Assessment Report Polish 30-03-2023
Patient Information leaflet Patient Information leaflet Portuguese 30-03-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 30-03-2023
Public Assessment Report Public Assessment Report Portuguese 30-03-2023
Patient Information leaflet Patient Information leaflet Romanian 30-03-2023
Public Assessment Report Public Assessment Report Romanian 30-03-2023
Patient Information leaflet Patient Information leaflet Slovak 30-03-2023
Public Assessment Report Public Assessment Report Slovak 30-03-2023
Patient Information leaflet Patient Information leaflet Slovenian 30-03-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 30-03-2023
Public Assessment Report Public Assessment Report Slovenian 30-03-2023
Patient Information leaflet Patient Information leaflet Finnish 30-03-2023
Public Assessment Report Public Assessment Report Finnish 30-03-2023
Patient Information leaflet Patient Information leaflet Swedish 30-03-2023
Public Assessment Report Public Assessment Report Swedish 30-03-2023
Patient Information leaflet Patient Information leaflet Norwegian 30-03-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 30-03-2023
Patient Information leaflet Patient Information leaflet Croatian 30-03-2023
Public Assessment Report Public Assessment Report Croatian 30-03-2023

Search alerts related to this product